Novo considers the next step for its oral insulin
Following a successful phase IIa study with its oral insulin candidate, Novo Nordisk is now assessing what it requires to move ahead with the important project. The company shelves development of two other drugs.
BY LOUISE WENDT JENSEN
Novo Nordisk has wrapped up and registered solid results from phase IIa trial with the candidate drug OI338GT, also known as NN1953.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novo Director: If someone is going to do it, it’s us
For abonnenter
Novo closing in on the Holy Grail
For abonnenter
US will be the focus of Novo’s H1 report
For abonnenter
